Literature DB >> 11428664

Expression and function of P-glycoprotein in rats with carbon tetrachloride-induced acute hepatic failure.

Z H Huang1, T Murakami, A Okochi, R Yumoyo, J Nagai, M Takano.   

Abstract

Acute hepatic failure was induced experimentally in rats by intraperitoneal injection of 2.5 mL kg(-1) carbon tetrachloride (CCl4), and the effects on the expression and function of P-glycoprotein in the liver, kidney and brain were evaluated. The CCl4 injection significantly increased the indicators of hepatic function (glutamate oxaloacetate transaminase, glutamate pyruvate transaminase), but not of renal function (blood urea nitrogen, glomerular filtration rate). In rats with acute hepatic failure, the hepatic P-glycoprotein concentration increased 1.5-fold and the ATP concentration decreased to approximately 40% that in control rats. In contrast, P-glycoprotein concentrations in the kidney and brain and ATP concentrations in the kidney remained unchanged. The in-vivo P-glycoprotein function in these tissues was suppressed as evaluated by biliary and renal secretory clearances and brain distribution of rhodamine 123, a P-glycoprotein substrate. These findings suggest that factors other than P-glycoprotein concentration are involved in the systemic suppression of P-glycoprotein function in diseased rats. In Caco-2 cells, plasma collected from CCl4-treated rats exhibited a greater inhibitory effect on P-glycoprotein-mediated transport of rhodamine 123 than that from control rats, suggesting the accumulation of an endogenous P-glycoprotein substrate/inhibitor in the plasma of diseased rats. In fact, the plasma concentration of corticosterone, an endogenous P-glycoprotein substrate, increased 2-fold in CCl4-treated rats compared with control rats. It was demonstrated that P-glycoprotein function is systemically suppressed in rats with CCl4-induced acute hepatic failure, not only in the target organ (liver), but also in other organs (kidney and brain), although the P-glycoprotein concentration remained unchanged in the kidney and brain, and increased in the liver. In the systemic suppression of the P-glycoprotein function in the diseased state, the alteration of plasma concentrations or components of endogenous P-glycoprotein-related compounds, such as corticosterone, would likely be involved.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11428664     DOI: 10.1211/0022357011776036

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  7 in total

1.  Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.

Authors:  Dagmar Kubitza; Angelika Roth; Michael Becka; Abir Alatrach; Atef Halabi; Holger Hinrichsen; Wolfgang Mueck
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

2.  Differential effect of acute hepatic failure on in vivo and in vitro P-glycoprotein functions in the intestine.

Authors:  Ryoko Yumoto; Teruo Murakami; Mikihisa Takano
Journal:  Pharm Res       Date:  2003-05       Impact factor: 4.200

3.  The Cytochrome P450-Mediated Metabolism Alternation of Four Effective Lignans From Schisandra chinensis in Carbon Tetrachloride-Intoxicated Rats and Patients With Advanced Hepatocellular Carcinoma.

Authors:  Rongrong Wu; Zhiyong Xiao; Xiaorui Zhang; Feng Liu; Wenxia Zhou; Yongxiang Zhang
Journal:  Front Pharmacol       Date:  2018-03-14       Impact factor: 5.810

Review 4.  Intestinal drug transporters in pathological states: an overview.

Authors:  Marek Drozdzik; Izabela Czekawy; Stefan Oswald; Agnieszka Drozdzik
Journal:  Pharmacol Rep       Date:  2020-07-27       Impact factor: 3.024

5.  Nitric oxide differentially regulates renal ATP-binding cassette transporters during endotoxemia.

Authors:  Suzanne Heemskerk; Arianne van Koppen; Luc van den Broek; Geert J M Poelen; Alfons C Wouterse; Henry B P M Dijkman; Frans G M Russel; Rosalinde Masereeuw
Journal:  Pflugers Arch       Date:  2007-02-07       Impact factor: 3.657

Review 6.  Alterations in Expression and Function of ABC Family Transporters at Blood-Brain Barrier under Liver Failure and Their Clinical Significances.

Authors:  Yilin Fan; Xiaodong Liu
Journal:  Pharmaceutics       Date:  2018-07-23       Impact factor: 6.321

Review 7.  Extrahepatic Drug Transporters in Liver Failure: Focus on Kidney and Gastrointestinal Tract.

Authors:  Marek Droździk; Stefan Oswald; Agnieszka Droździk
Journal:  Int J Mol Sci       Date:  2020-08-10       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.